The table below shows AbCellera Biologics Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$33.52M
-$11.55M
-$41.71M
-$44.06M
$100.22M
$109.55M
Capital expenditure
$3.83M
$10.64M
$24.14M
$14.98M
$14.49M
$3.64M
Investing cash flow
-$25.08M
$7.93M
$29.91M
-$149.61M
-$26.37M
-$15.84M
Dividends paid
-
-
-
ABCL operating cash flow (10-K history)
AbCellera Biologics Inc. reported operating cash flow of -$131.29M for fiscal year 2025. That is down 20.9% from -$108.56M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $2.69M (FY 2019) to -$131.29M. Figures come from the company's audited annual reports as filed with the SEC.
